Alice Mcknight Garner

Learn More
PURPOSE To evaluate the feasibility of administering BAY 12-9566, a matrix metalloproteinase (MMP) inhibitor with relative specificity against MMP-2, MMP-3, and MMP-9, on a protracted oral daily dosing schedule in patients with advanced solid malignancies. The study also sought to determine the principal toxicities of BAY 12-9566, whether plasma BAY 12-9566(More)
Human sulfotransferase 1A1 (SULT1A1) is involved in the metabolism of a number of substances including 4-hydroxytamoxifen. It has been shown that patients who are homozygous for the variant SULT1A1 *2/*2 have lower catalytic activity. Previous data has suggested that patients with this particular genotype may be at a greater risk of developing breast cancer(More)
PURPOSE To assess the feasibility of administering PN401, an oral uridine prodrug, as a rescue agent for the toxic effects of fluorouracil (5-FU), and to determine the maximum-tolerated dose of 5-FU when given with PN401, with an 8-hour treatment interval between these agents. PATIENTS AND METHODS Patients with advanced solid malignancies were treated(More)
PURPOSE To evaluate the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetic profile of vesnarinone given once daily in combination with gemcitabine. PATIENTS AND METHODS Twenty-six patients were treated with oral vesnarinone once daily on a continuous schedule at doses of 60, 90, 120, 150, and 180 mg in combination with(More)
Cerebral vascular injury is common in bacterial meningitis, but the role of microbial factors associated with this phenomenon is unclear.Escherichia coli S-fimbriae and outer membrane protein A (OmpA) have been shown to promote binding and invasion of E. coli to brain microvascular endothelial cells, respectively. Using the cranial window model, we compared(More)
505 Background: Tamoxifen (TAM) and its metabolites display large inter-individual variation with profound implications for breast cancer outcomes. Tamoxifen is hydroxylated to the potent metabolites, 4-hydroxytamoxifen (4-OH TAM) and endoxifen, by various cytochrome P450 (CYP450) genes including CYP2C9 and CYP2D6. The SULT1A1 gene is involved in the(More)
Neonatal sepsis has been described as a “ low-incidence, highrisk” disease, with an incidence of 0.8 to 8 per thousand live births. Despite its low incidence, the subsequent morbidity and mortality are high. Consequently, clinicians are searching for a method that could identify infected infants needing treatment with close to 100% sensitivity and that(More)